Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury
Michał Wiciński, Eryk Wódkiewicz, Karol Górski, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 11, pp. 379-379
Open Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Targeting ROS-Dependent AKT/GSK-3β/NF-κB and DJ-1/Nrf2 Pathways by Dapagliflozin Attenuates Neuronal Injury and Motor Dysfunction in Rotenone-Induced Parkinson’s Disease Rat Model
Hany H. Arab, Marwa M. Safar, Nancy N. Shahin
ACS Chemical Neuroscience (2021) Vol. 12, Iss. 4, pp. 689-703
Closed Access | Times Cited: 122
Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment
Maria Rosaria Rizzo, Irene Di Meo, Rita Polito, et al.
Pharmacological Research (2022) Vol. 176, pp. 106062-106062
Open Access | Times Cited: 101
The molecular link between oxidative stress, insulin resistance, and type 2 diabetes: A target for new therapies against cardiovascular diseases
Aikaterini Andreadi, Alfonso Bellia, Nicola Di Daniele, et al.
Current Opinion in Pharmacology (2021) Vol. 62, pp. 85-96
Closed Access | Times Cited: 87
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Kai‐Fan Tsai, Yung‐Lung Chen, Terry Ting-Yu Chiou, et al.
Antioxidants (2021) Vol. 10, Iss. 8, pp. 1166-1166
Open Access | Times Cited: 79
Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
Stephanie Kullmann, Julia Hummel, Róbert Wágner, et al.
Diabetes Care (2021) Vol. 45, Iss. 2, pp. 398-406
Open Access | Times Cited: 73
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
Jonathan V Mui, Jiandong Zhou, Sharen Lee, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 71
Alzheimer’s disease and type 2 diabetes mellitus: Pathophysiologic and pharmacotherapeutics links
Milagros Rojas, Mervin Chávez-Castillo, Jordan Bautista, et al.
World Journal of Diabetes (2021) Vol. 12, Iss. 6, pp. 745-766
Open Access | Times Cited: 61
Empagliflozin alleviates endoplasmic reticulum stress and augments autophagy in rotenone-induced Parkinson's disease in rats: Targeting the GRP78/PERK/eIF2α/CHOP pathway and miR-211-5p
Tarek K. Motawi, Rawan H. Al-Kady, Sahar M. Abdelraouf, et al.
Chemico-Biological Interactions (2022) Vol. 362, pp. 110002-110002
Closed Access | Times Cited: 48
Chronic Kidney Disease and Cognitive Impairment: The Kidney-Brain Axis
Zuoquan Xie, Siyu Tong, Xingkun Chu, et al.
Kidney Diseases (2022) Vol. 8, Iss. 4, pp. 275-285
Open Access | Times Cited: 43
Type 2 diabetes mellitus and cognitive function: understanding the connections
Lisa Dao, Sarah Choi, Matthew Freeby
Current Opinion in Endocrinology Diabetes and Obesity (2022) Vol. 30, Iss. 1, pp. 7-13
Closed Access | Times Cited: 43
Dapagliflozin as an autophagic enhancer via LKB1/AMPK/SIRT1 pathway in ovariectomized/d-galactose Alzheimer’s rat model
Weam W. Ibrahim, Ahmed S. Kamel, Ahmed Wahid, et al.
Inflammopharmacology (2022) Vol. 30, Iss. 6, pp. 2505-2520
Open Access | Times Cited: 38
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
Bains Jasleen, Gupta K Vishal, Malepati Sameera, et al.
Cureus (2023)
Open Access | Times Cited: 37
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
Mahmoud E. Youssef, Galal Yahya, Mihaela Simona Popoviciu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6039-6039
Open Access | Times Cited: 37
Unveiling the impact of aging on BBB and Alzheimer's disease: Factors and therapeutic implications
Niraj Kumar Jha, Niraj Kumar Jha, Mohana Vamsi Nuli, et al.
Ageing Research Reviews (2024) Vol. 98, pp. 102224-102224
Closed Access | Times Cited: 14
SGLT2i and Cardiovascular Events in Patients With Concomitant Atrial Fibrillation and Diabetes: A TriNetX Cohort Study
Yu–Yu Hsiao, Yun‐Yu Chen, Ming‐Jen Kuo, et al.
The Journal of Clinical Endocrinology & Metabolism (2025)
Open Access | Times Cited: 1
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias
Huilin Tang, William T. Donahoo, Steven T. DeKosky, et al.
JAMA Neurology (2025)
Closed Access | Times Cited: 1
Crosstalk Among NLRP3 Inflammasome, ETBR Signaling, and miRNAs in Stress-Induced Depression-Like Behavior: a Modulatory Role for SGLT2 Inhibitors
Radwa N. Muhammad, Lamiaa A. Ahmed, Rania M. Abdul Salam, et al.
Neurotherapeutics (2021) Vol. 18, Iss. 4, pp. 2664-2681
Open Access | Times Cited: 45
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
Marvin Heimke, Florian Lenz, Uta Rickert, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3107-3107
Open Access | Times Cited: 31
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
André Scheen, Fabrice Bonnet
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101419-101419
Open Access | Times Cited: 20
Diabetes-Alzheimer's connection in older age: SGLT2 inhibitors as promising modulators of disease pathways
Francesca Mancinetti, Dionysios P. Xenos, Michelantonio De Fano, et al.
Ageing Research Reviews (2023) Vol. 90, pp. 102018-102018
Closed Access | Times Cited: 20
Crosstalk between Alzheimer’s disease and diabetes: a focus on anti-diabetic drugs
Golnaz Goodarzi, Sadra Samavarchi Tehrani, Saeed Ebrahimi Fana, et al.
Metabolic Brain Disease (2023) Vol. 38, Iss. 6, pp. 1769-1800
Closed Access | Times Cited: 19
Dapagliflozin Ameliorates Cognitive Impairment in Aluminum-Chloride-Induced Alzheimer’s Disease via Modulation of AMPK/mTOR, Oxidative Stress and Glucose Metabolism
Waad A. Samman, Salma Selim, Hassan M. El Fayoumi, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 5, pp. 753-753
Open Access | Times Cited: 18
Glucose Transport and Utilization in the Hippocampus: From Neurophysiology to Diabetes-Related Development of Dementia
Caio Yogi Yonamine, Maria Luiza Estimo Michalani, Rafael Junges Moreira, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16480-16480
Open Access | Times Cited: 17
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Magdalena Złotek, Antonina Kurowska, Mariola Herbet, et al.
Biomedicines (2023) Vol. 11, Iss. 11, pp. 3035-3035
Open Access | Times Cited: 16
Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
Adelene Y. L. Sim, Sumit Barua, Jong Youl Kim, et al.
Frontiers in Neuroscience (2021) Vol. 15
Open Access | Times Cited: 40
Page 1 - Next Page

Scroll to top